<tei>
    <teiHeader>
        <fileDesc xml:id="_Maurer 2018.pdf"/>
    </teiHeader>
    <text xml:lang="en">


        <figure>

            <head>Figure </head>
 
            <label>1</label>

            <head>. </head>
 
            <figDesc>Randomization, Evaluation, and Outcomes.</figDesc>
        </figure>


        <figure>

            <head>Figure </head>
 
            <label>2</label>

            <head>. </head>
 
            <figDesc>Primary Analysis and Components.</figDesc>
        </figure>


        <figure>

            All-Cause Mortality<lb/> C Frequency of Cardiovascular-Related Hospitalizations<lb/> A Primary Analysis, with Finkelstein-Schoenfeld Method<lb/> Probability of Survival<lb/> 1.0<lb/> 0.8<lb/> 0.9<lb/> 0.7<lb/> 0.6<lb/> 0.4<lb/> 0.3<lb/> 0.1<lb/> 0.5<lb/> 0.2<lb/> 0.0<lb/> 0<lb/> 6<lb/> 9<lb/> 12<lb/> 15<lb/> 18<lb/> 33</content>
        </figure>


        <figure>

            <head>Figure </head>
 
            <label>3</label>

            <head>. </head>
 
            <figDesc>Overall and Subgroup Results as Calculated with the Use of the Finkelstein-Schoenfeld Method, All-Cause Mortality,<lb/> and Cardiovascular-Related Hospitalizations.</figDesc>
        </figure>


        <figure>

            <head>Figure </head>
 
            <label>4</label>

            <head>. </head>
 
            <figDesc>Key Secondary End Points.<lb/> Panel A shows the least-squares (LS) mean (±SE) change from baseline<lb/> to month 30 in the distance walked in the 6-minute walk test in the pooled<lb/> tafamidis group as compared with the placebo group. Panel B shows the<lb/> LS mean (±SE) change from baseline for both groups in the Kansas City<lb/> Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score, in<lb/> which higher scores indicate better health status. I bars indicated standard<lb/> errors.<lb/> </figDesc>

            <lb/> LS Mean Change from Baseline (m)<lb/> 0<lb/> −60<lb/> −30<lb/> −90<lb/> −150<lb/> −120<lb/> −180<lb/> 0<lb/> 6<lb/> 12<lb/> 18<lb/> 24<lb/> 30<lb/> Month<lb/> B Change from Baseline in KCCQ-OS<lb/> A Change from Baseline in 6-Minute Walk Test<lb/> No. of Patients<lb/> Tafamidis<lb/> Placebo<lb/> 264<lb/> 177<lb/> 233<lb/> 147<lb/> 216<lb/> 136<lb/> 193<lb/> 111<lb/> 163<lb/> 85<lb/> 155<lb/> 70<lb/> Pooled tafamidis<lb/> Placebo<lb/> LS Mean Change from Baseline<lb/> 0<lb/> −20<lb/> −10<lb/> −30<lb/> 0<lb/> 6<lb/> 12<lb/> 18<lb/> 24<lb/> 30<lb/> Month<lb/> No. of Patients<lb/> Tafamidis<lb/> Placebo<lb/> 264<lb/> 177<lb/> 241<lb/> 159<lb/> 221<lb/> 145<lb/> 201<lb/> 123<lb/> 181<lb/> 96<lb/> 170<lb/> 84<lb/> Pooled tafamidis<lb/> Placebo<lb/> P&lt;0.001<lb/> P&lt;0.001<lb/> The New England </content>
 
            <figDesc>Journal of Medicine<lb/> Downloaded from nejm.org on November 9, 2022. For personal use only. No other uses without permission.<lb/> Copyright © 2018 Massachusetts Medical Society. All rights reserved.<lb/> n engl j med 379;11 nejm.org September 13, 2018<lb/> 1015<lb/> Tafamidis for Tr ansthyretin Amyloid Cardiomyopathy</figDesc>
        </figure>



    </text>
</tei>

